CStone’s MEK Inhibitor CS3006 Receives IND Approval in China

SUZHOU, China, July 30, 2018 /PRNewswire/ — CStone Pharmaceuticals (CStone) today announced that its IND application for CS3006, a small-molecule inhibitor of mitogen-activated protein kinase (MEK), has been approved by the China National Drug Administration (CNDA) for clinical trials,…

Source: https://www.prnewswire.com:443/news-releases/cstones-mek-inhibitor-cs3006-receives-ind-approval-in-china-300688262.html

About the Author

has written 20650 stories on this site.

Copyright © 2010-2019 strategicbusinessnews.com